Derivation and Characterization of Bovine Induced Pluripotent Stem Cells by Transposon-Mediated Reprogramming

Talluri, Thirumala Rao; Kumar, Dharmendra; Glage, Silke; Garrels, Wiebke; Ivics, Zoltán; Debowski, Katharina; Behr, Rüdiger; Niemann, Heiner; Kues, Wilfried A.

doi:10.1089/cell.2014.0080

Cited by 73 publications

(68 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ESCs and iPSCs are obtained from many animal species: bovine (Bogliotti et al, 2018;Han et al, 2011;Talluri et al, 2015); swine (Chakritbudsabong et al, 2017;Ezashi et al, 2009;Siriboon et al, 2015); horses (Quattrocelli et al, 2016;Tecirlioglu & Trounson, 2007);…”

Section: Species-specific Induced Pluripotent Stem Cell and Embryonmentioning

confidence: 99%

Organoids are promising tools for species‐specific in vitro toxicological studies

Augustyniak

Bertero

Coccini³

et al. 2019

J of Applied Toxicology

View full text Add to dashboard Cite

Organoids are three‐dimensional self‐aggregating structures generated from stem cells (SCs) or progenitor cells in a process that recapitulates molecular and cellular stages of early organ development. The differentiation process leads to the appearance of specialized mature cells and is connected with changes in the organoid internal structure rearrangement and self‐organization. The formation of organ‐specific structures in vitro with highly ordered architecture is also strongly influenced by the extracellular matrix. These features make organoids as a powerful model for in vitro toxicology. Nowadays this technology is developing very quickly. In this review we present, from a toxicological and species‐specific point of view, the state of the art of organoid generation from adult SCs and pluripotent SCs: embryonic SCs or induced pluripotent SCs. The current culture organoid techniques are discussed for their main advantages, disadvantages and limitations. In the second part of the review, we concentrated on the characterization of species‐specific organoids generated from tissue‐specific SCs of different sources: mammary (bovine), epidermis (canine), intestinal (porcine, bovine, canine, chicken) and liver (feline, canine).

show abstract

Section: Species-specific Induced Pluripotent Stem Cell and Embryonmentioning

confidence: 99%

Organoids are promising tools for species‐specific in vitro toxicological studies

Augustyniak

Bertero

Coccini³

et al. 2019

J of Applied Toxicology

View full text Add to dashboard Cite

show abstract

“…Relative to the embryonic stem cell lines, studies on iPSCs in large animals has made more progress, especially for pigs. However, there are still some difficulties, cell propagation is dependent on exogenous genes and cannot produce germline chimeric offspring [59,127,130,164,165] . These problems need to be solved urgently for the study of PSCs in large animals.…”

Section: Challenges and Prospectsmentioning

confidence: 99%

Porcine pluripotent stem cells: progress, challenges and prospects

Han¹,

Miao²,

Hua³

et al. 2019

Front. Agr. Sci. Eng.

View full text Add to dashboard Cite

Pluripotent stem cells (PSCs) are characterized by their capacity for high self-renewal and multiple differentiation potential and include embryonic stem cells, embryonic germ cells and induced PSCs. PSCs provide a very suitable model for the studies of human diseases, drugs screening, regenerative medicine and developmental biology research. Pigs are considered as an ideal model for preclinical development of human xenotransplantation, therapeutic approaches and regenerative medicine because of their size and physiological similarity to humans. However, lack of knowledge about the derivation, characterization and pluripotency mechanisms of porcine PSCs hinders progress in these biotechnologies. In this review, we discuss the latest progress on porcine PSCs generation, evaluation criteria for pluripotency, the scientific and technical questions arising from these studies. We also introduce our perspectives on porcine PSC research, in the hope of providing new ideas for generating naive porcine PSCs and animal breeding.

show abstract

“…107 Both SB-and PB-based transposons have been employed to express these reprogramming factors and successfully reprogram mouse, [108][109][110] bovine, 111,112 porcine, 113 and human 110,114,115 fibroblasts into iPS cells. Direct comparative analysis between hyPBase-and SB100X-mediated gene transfer showed that both systems displayed comparable reprogramming efficiency.…”

Section: Hscmentioning

confidence: 99%

Transposons: Moving Forward from Preclinical Studies to Clinical Trials

Tipanee¹,

VandenDriessche

Chuah

2017

Human Gene Therapy

View full text Add to dashboard Cite

Transposons have emerged as promising vectors for gene therapy that can potentially overcome some of the limitations of commonly used viral vectors. Transposons stably integrate into the target cell genome, enabling persistent expression of therapeutic genes. Transposons have evolved from being used as basic tools in biomedical research to bona fide therapeutics. Currently, the most promising transposons for gene therapy applications are derived from Sleeping Beauty (SB) or piggyBac (PB). Stable transposition requires co-delivery of the transposon DNA with the corresponding transposase gene, mRNA, or protein. Stable transposition efficiency can be substantially increased by using "next-generation" transposon systems that combine codon-usage optimization with hyper-activating mutations in the SB or PB transposases. By virtue of their relatively large capacity, gene therapy applications with relatively large therapeutic transgenes, such as full-length dystrophin, can now be envisaged. The authors and others have shown that efficient and stable gene transfer can be achieved with these next-generation transposons in several clinically relevant primary cells, such as CD34 hematopoietic stem/progenitor cells, T cells, and mesenchymal and myogenic stem/progenitor cells that are amenable for ex vivo transfection. Alternatively, in vivo transposon gene delivery has been explored using non-viral vectors or nanoparticles or in combination with viral vectors. The therapeutic potential of these SB- and PB-based transposons has been demonstrated in preclinical models that mimic the cognate human diseases. However, there are still challenges impeding clinical translation of transposons pertaining mainly to the typical limiting efficiencies of most non-viral transfection methods and the intrinsic DNA toxicity. Nevertheless, it is particularly encouraging that transposons have now been used in gene therapy clinical trials. In particular, transposon-engineered T cells expressing chimeric antigen receptors are starting to yield promising results in patients with hematological malignancies.

show abstract

Derivation and Characterization of Bovine Induced Pluripotent Stem Cells by Transposon-Mediated Reprogramming

Cited by 73 publications

References 73 publications

Organoids are promising tools for species‐specific in vitro toxicological studies

Organoids are promising tools for species‐specific in vitro toxicological studies

Porcine pluripotent stem cells: progress, challenges and prospects

Transposons: Moving Forward from Preclinical Studies to Clinical Trials

Contact Info

Product

Resources

About